Galectin, Comstock, Cooper, Nutrien, Monday: Trending by Analysts

Analysts are intrested in these 5 stocks: ( (GALT) ), ( (CRK) ), ( (COO) ), ( (NTR) ) and ( (MNDY) ). Here is a breakdown of their recent ratings and the rationale behind them.

Galectin Therapeutics is making waves with its lead asset, belapectin, which is the only therapy in development for MASH cirrhosis and portal hypertension. Analyst Matthew Keller has initiated coverage with a Buy rating and a $6 price target. Despite some bumps in its clinical journey, belapectin has shown promise, particularly in a subgroup of patients with MASH cirrhosis without varices. The NAVIGATE trial, although not statistically significant in its primary endpoint, showed a significant reduction in varices in a pre-specified population, indicating potential for belapectin in earlier-stage therapy.

Comstock Resources is catching the attention of investors with its strategic land acquisitions and resource expansion in the Western Haynesville area. Analyst Carlos Escalante has upgraded the stock to Buy with a $34 price target, highlighting the company’s shift from a DCF valuation to a resource-based one. With a focus on proving resource depth and a strong drilling backlog, CRK is well-positioned to capitalize on elevated gas prices and potential M&A opportunities, making it a compelling investment case.

Cooper Co has been upgraded to Buy by analyst David Saxon, who sees an attractive entry point due to a dislocation between the company’s valuation and fundamentals. With positive growth outlooks and strong management meetings, COO is poised for significant EPS potential by FY26. The company’s strategic initiatives and participation in various investor meetings further bolster confidence in its future performance, making it a stock to watch.

Nutrien has been downgraded to Hold by analyst Steve Hansen, following a period of solid share price appreciation. Despite recent gains and strong potash contract settlements, the upside appears limited due to affordability concerns and seasonal factors. While the company continues to make progress towards its long-term goals, the current dynamics suggest a more cautious approach is warranted until a more attractive entry point presents itself.

Monday.com is embarking on a transformative journey, moving upmarket and expanding its product offerings. Analyst Josh Baer has initiated coverage with a Hold rating and a $330 price target, noting the company’s strong execution and growth potential. However, the shift to a sales-led growth motion and new market opportunities come with inherent risks. While the company’s current position is strong, significant investments are needed to sustain its evolution, making it a stock with moderate upside potential.